CDKN2B and lymphoma: MYCV394D is unable to repress wild-type MYC targets such as Cyclin Dependent Kinase Inhibitor 1A (CDKN1A/p21CIP) and Cyclin Dependent Kinase Inhibitor 2B (CDKN2B/p15INK4B), in a transgenic lymphoma model [69].